Contact Us
Drug Search Results
More Filters [+]

CF33-hNIS

Alternative Names: CF33-hNIS, Vaxinia, CF33hNIS
Latest Update: 2024-12-31
Latest Update Note: Clinical Trial Update

Product Description

CF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32032721/)

Mechanisms of Action: PD-L1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intramuscular,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Imugene
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CF33-hNIS

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Bile Duct Cancer|Cholangiocarcinoma|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCI-2021-08983

P1

Active, not recruiting

Triple Negative Breast Cancer

2025-06-22

MAST

P1

Recruiting

Cholangiocarcinoma|Bile Duct Cancer

2024-12-01

27%

Recent News Events

Date

Type

Title

04/15/2024

News Article

 Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort

04/09/2024

News Article

 Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

04/08/2024

News Article

 City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

02/22/2024

News Article

 Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

11/10/2023

PubMed

 CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.

09/16/2023

PubMed

 Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients.

06/15/2023

PubMed

 Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions